RRx-001, an epigenetic-based radio- and chemosensitizer, has vascular normalizing effects on SCCVII and U87 tumors

BACKGROUND: The tumor-specific microregional effects of the anticancer agent RRx-001, a novel epigenetic-based radio/chemosensitizer with nitrogen oxide-donating properties in phase II clinical trials, were investigated with whole tissue section quantitative immunohistological staining in mouse SCCV...

Descripción completa

Detalles Bibliográficos
Autores principales: Oronsky, Bryan, Scicinski, Jan, Cabrales, Pedro, Minchinton, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4864927/
https://www.ncbi.nlm.nih.gov/pubmed/27175220
http://dx.doi.org/10.1186/s13148-016-0220-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4864927/
https://www.ncbi.nlm.nih.gov/pubmed/27175220
http://dx.doi.org/10.1186/s13148-016-0220-7

Ejemplares similares